Primary Cutaneous Amyloidosis Associated With Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndrome and Sjögren Syndrome: A Case Report | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Primary Cutaneous Amyloidosis Associated With Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndrome and Sjögren Syndrome: A Case Report

key information

source: Medicine

year: 2018

authors: Yan X1, Jin J

summary/abstract:

Patient concerns:
A 50-year-old woman presented with progressive abnormal liver enzyme levels and was referred to our department.
 
Diagnoses:
Due to the patient’s symptoms, laboratory test results, radiographic findings, and pathologic results, she was diagnosed with PCA associated with AIH-PBC overlap syndrome and SS.
 
Interventions:
She was subsequently treated with a combination of ursodeoxycholic acid (UDCA), prednisone, and azathioprine.
 
Outcomes:
While this treatment can achieve therapeutic success, it cannot prevent complications from cirrhosis. This patient remains alive but experienced an emergent gastrointestinal hemorrhage.
 
Lessons:
While we acknowledge that this is a single case, these findings extend our knowledge of immunological diseases associated with PCA and suggest a common, immune-mediated pathogenic pathway between PCA, AIH-PBC overlap syndrome, and SS. After 12 years of follow up, clinical manifestations have developed, and these autoimmune diseases have progressed. The combination of UDCA, prednisone, and azathioprine can achieve therapeutic success but cannot prevent disease progression. Routine follow up for this patient is necessary to document disease progression.
 
organization: The First Hospital of Jilin University, China

DOI: 10.1097/MD.0000000000010004

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close